Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.)

Comment

Awadhesh Kumar Singh et al. Diabetes Metab Syndr. 2020 Sep-Oct.

. 2020 Sep-Oct;14(5):729.

doi: 10.1016/j.dsx.2020.05.030. Epub 2020 May 23.

No abstract available

Comment on

Letter in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.).
Mahajan K, Gaur N. Mahajan K, et al. Diabetes Metab Syndr. 2020 Sep-Oct;14(5):723-724. doi: 10.1016/j.dsx.2020.05.029. Epub 2020 May 23. Diabetes Metab Syndr. 2020. PMID: 32473902 Free PMC article. No abstract available.

1. Singh A.K., Gupta R., Misra A. Comorbidities in COVID-19: outcomes in hypertensivecohort and controversies with renin angiotensin system blockers. Diabetes Metabol Syndrome Res Rev. 2020 Apr 9;14(4):283–287. - PMC - PubMed
1. Towler P., Staker B., Prasad S.G. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J Biol Chem. 2004 Apr;279(17):17996–18007. - PMC - PubMed
1. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. doi:10.1001/jamacardio.2020.1017. Published online March 27, 2020. - PMC - PubMed
1. Million M., Lagier J.C., Gautret P. Bibliovid; 2020. Early treatment of 1061 COVID-19 patients with hydroxychloroquine and azithromycin, Marseille, France.https://www.mediterranee-infection.com/early-treatment-of-1061-covid-19-... - PMC - PubMed
1. Zhang P., Zhu L., Cai J., Lei F., Quin J.J., Xie J. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020 Apr 17 doi: 10.1161/CIRCRESAHA.120.317134. [Epub ahead of print] - DOI - PMC - PubMed